Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy

被引:49
作者
Etrych, Tomas
Mrkvan, Tomas
Rihova, Blanka
Ulbrich, Karel
机构
[1] Acad Sci Czech Republic, Inst Macromol Chem, Prague 16206 6, Czech Republic
[2] Acad Sci Czech Republic, Inst Microbiol, Prague 14240 4, Czech Republic
关键词
water-soluble polymers; drug delivery systems; doxorubicin; drug release; human immunoglobulin (Hulg);
D O I
10.1016/j.jconrel.2007.06.007
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Synthesis and preliminary anticancer activity of new star-shaped immunoglobulin-containing polymer-doxorubicin (DOX) conjugates were investigated. The polymer precursors used for the synthesis of immunoglobulin-polymer-drug conjugates are based on N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers, the anticancer drug DOX is attached to the immunoglobulin-modified polymer via a pH-sensitive hydrazone linkage. Such polymer-DOX conjugates are stable in aqueous solution at pH 7.4 (pH of blood plasma) and the drug is released in mildly acid environment at pH 5-5.5 (pH in endosomes or lysosomes of target cells). Semitelechelic copolymer chains are linked to the immunoglobulin via one-point attachment to avoid branching of the conjugate observed in our earlier studied systems. The cytostatic activity of the conjugates tested on several cancer cell lines was similar to that of free DOX-HCl and correlated with the sensitivity of a particular cell line to DOX. The star-shaped conjugates containing immunoglobulin showed a significantly higher antitumor activity in vivo than immunoglobulin-free non-targeted polymer conjugates when tested in mice bearing EL4 T-cell lymphoma. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:31 / 38
页数:8
相关论文
共 28 条
[11]   HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia [J].
Kovár, M ;
Mrkvan, T ;
Strohalm, J ;
Etrych, T ;
Ulbrich, K ;
Stastny, M ;
Ríhová, B .
JOURNAL OF CONTROLLED RELEASE, 2003, 92 (03) :315-330
[12]   Drug-polymer conjugates containing acid-cleavable bonds [J].
Kratz, F ;
Beyer, U ;
Schütte, MT .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 1999, 16 (03) :245-288
[13]   The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting [J].
Maeda, H .
ADVANCES IN ENZYME REGULATION, VOL 41, 2001, 41 :189-207
[14]   Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity [J].
Mrkvan, T ;
Sirova, M ;
Etrych, T ;
Chytil, P ;
Strohalm, J ;
Plocova, D ;
Ulbrich, K ;
Rihova, B .
JOURNAL OF CONTROLLED RELEASE, 2005, 110 (01) :119-129
[15]  
Putnam D, 1995, ADV POLYM SCI, V122, P55, DOI 10.1007/3540587888_14
[16]  
Ríhová B, 2000, J CONTROL RELEASE, V64, P241
[17]   Antiproliferative effect of a lectin- and anti-Thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse Thy-1.2 gene [J].
Ríhová, B ;
Jelínková, M ;
Strohalm, J ;
St'astny, M ;
Hovorka, O ;
Plocová, D ;
Kovár, M ;
Dráberová, L ;
Ulbrich, K .
BIOCONJUGATE CHEMISTRY, 2000, 11 (05) :664-673
[18]   Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes [J].
Ríhová, B ;
Etrych, T ;
Pechar, M ;
Jelínková, M ;
Stastny, M ;
Hovorka, O ;
Kovar, M ;
Ulbrich, K .
JOURNAL OF CONTROLLED RELEASE, 2001, 74 (1-3) :225-232
[19]  
SCHACHT EH, 1996, PRACTICE MED CHEM, P717
[20]   Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice [J].
Sirova, Milada ;
Strohalm, Jiri ;
Subr, Vladimir ;
Plocova, Daniela ;
Rossmann, Pavel ;
Mrkvan, Tomas ;
Ulbrich, Karel ;
Rihova, Blanka .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (01) :35-47